Peptide Radar

BPC-157 vs TB-500: how the evidence compares

PR
Peptide Radar Research Desk
Independent evidence aggregator. Not a clinic, not medical advice. · Updated 2026-07-21 · How we grade evidence
Both are marketed for recovery and frequently combined. Both are largely preclinical, both are scheduled for FDA committee review on July 23, 2026, and neither has robust human trials establishing the marketed uses.

Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.

Body Protection Compound 157

A synthetic 15-amino-acid peptide marketed for gut, tendon and injury recovery. Human evidence is minimal; the FDA staff briefing proposed not adding it to the 503A compounding list.

ClaimEvidence
Gut / ulcerative colitisR
Tendon / injury recoveryC
General anti-inflammatoryC

Thymosin beta-4 fragment

A synthetic fragment of thymosin beta-4 marketed for tissue repair and recovery. FDA did not identify human administration data; injectable-route risks were flagged.

ClaimEvidence
Wound healingR
Tissue / sports recoveryC
Injury repairC

Get the regulation & evidence watchlist

Choose your main interest, then get one email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.

What do you most want updates about?

Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.